Chimeric antigen receptor (CAR) T therapy represents an exciting and promising modality for cancer treatment, evidenced by approvals of Kymriah and Yescarta. The potential of this new technology is massive. However, it is widely recognised that complex and lengthy manufacturing requirements have resulted in these therapies costing > £240,000 per treatment, limiting its widespread use. ImmTune Therapies is an early stage biotechnology startup focusing on tackling these issues of manufacturing and high costs. By designing a novel vector system which can genetically engineer T cells specifically inside the patient’s body, we have developed the next generation immunotherapy unlocking the full potential of these adoptive cell therapies (ACT). The commercial development of an in vivo treatment represents a highly innovative opportunity to redefine how ACT is applied and will provide a great boost to these cell and gene therapies.